CN Patent

CN108299294A — 一种乐伐替尼杂质的制备方法

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2018-07-20 · 8y expired

What this patent protects

本发明提供了一种乐伐替尼杂质的制备方法。具体而言，本发明提供了乐伐替尼杂质4,4'‑[4,4'‑羰基双(脲二基)双(3‑氯‑4,1‑次苯基)]双(氧)双(7‑甲氧基喹啉‑6‑羧酰胺)的制备方法。

USPTO Abstract

本发明提供了一种乐伐替尼杂质的制备方法。具体而言，本发明提供了乐伐替尼杂质4,4'‑[4,4'‑羰基双(脲二基)双(3‑氯‑4,1‑次苯基)]双(氧)双(7‑甲氧基喹啉‑6‑羧酰胺)的制备方法。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN108299294A
Jurisdiction: CN
Classification: —
Expires: 2018-07-20
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.